COVID-19 Rapid Assessment
The CDPE is leading a rapid assessment of the COVID-19 pandemic’s impact on people who inject drugs in Toronto.
Project Contents
Overview
The COVID-19 pandemic has exacerbated the overdose crisis in Toronto, with record increases in the number of overdose fatalities. Mandated physical distancing and service closures have limited the capacity of clinicians and service providers to provide care and support for people who inject drugs.
In response, the CDPE is leading a rapid assessment of the impact of the COVID-19 pandemic on people who inject drugs in Toronto, including clinical and social outcomes, service utilization, and trends in the unregulated drug supply. Unhoused or underhoused subpopulations of people who inject drugs are a focus of this assessment, as they are disproportionately at risk of overdose, are often immunocompromised, and can face serious chronic conditions – putting them at higher risk for SARS-CoV-2 infections and severe COVID-19 disease.
Building upon the Integrated Supervised Injection Services (OiSIS) Evaluation led by the CDPE, this rapid assessment includes quantitative surveys and qualitative interviews with cohort participants about the effects of COVID-19 on their lives. In addition, the rapid assessment tracks participant clinical outcomes over time through an administrative health data linkage with ICES. We are also analyzing service utilization data from harm reduction services across the city, including Toronto’s drug checking service. Using mixed methods approaches, the rapid assessment will yield critical findings on the social and public health consequences of COVID-19 on people who inject drugs to inform improvements to policy and clinical practice.
Financial Supporters
Canadian Institutes of Health Research | Canadian Research Initiative in Substance Misuse | St. Michael’s Hospital Foundation
Partners
British Columbia Centre on Substance Use| Centre for Addiction and Mental Health | Canadian Research Initiative in Substance Misuse | Moss Park Consumption and Treatment Service | Parkdale Queen West Community Health Centre | South Riverdale Community Health Centre | St. Michael’s Hospital | The Works at Toronto Public Health
Project Contact
Dr. Dan Werb
dan@cdpe.org
Related Content

T-DOT (Toronto Disparities, Overdose and Treatment), formerly OiSIS
T-DOT (Toronto Disparities, Overdose and Treatment) is an ongoing cohort study that started in 2018 (formerly OiSIS) of people who use drugs, looking at supervised consumption sites, drug checking, treatment, and the continuum of care. Sub-studies include: Injectable Opioid Agonist Treatment (iOAT) and Safer Opioid Supply (SOS or Prescribed Alternatives) program evaluations in Toronto.
View
Piloting and Evaluating Drug Checking Services in Toronto, Ontario
The pilot for Toronto’s Drug Checking Service, which checked and publicly reported on more than 10,000 samples between October 10, 2019, and June 30, 2023, was coordinated by the CDPE. While Toronto’s Drug Checking Service now operates from its own unit within MAP Centre for Urban Health Solutions at St. Michael’s Hospital, a site of Unity Health Toronto, the CDPE continues to work collaboratively with and conduct scientific research on the program.
View
Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions
In March 2020, following a provincial COVID-19 emergency declaration, modifications to opioid agonist treatment (OAT) were introduced in Ontario, Canada to promote treatment access amid the pandemic and ongoing opioid overdose crisis. Our objectives were to evaluate the effects of these modifications on OAT enrollment and on receipt of take-home doses and the frequency of urine drug screening among OAT-enrolled participants, as well as to investigate concurrent pre- and post-implementation trends in opioid-related overdoses and all-cause mortality.
View
The Ontario Integrated Supervised Injection Services Cohort Study of People Who Inject Drugs in Toronto, Canada (OiSIS-Toronto): Cohort Profile
The Ontario Integrated Supervised Injection Services cohort in Toronto, Canada (OiSIS-Toronto) is an open prospective cohort of people who inject drugs established to evaluate the impacts of supervised consumption services integrated within three community health agencies on health status and service use.
View
Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications
We report the first detection of the psychoactive veterinary compound xylazine in Toronto, the largest urban center in Canada, by the city’s drug checking service.
View
Preliminary Patterns in Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic
The Ontario Drug Policy Research Network, the Office of the Chief Coroner for Ontario/the Ontario Forensic Pathology Service, Public Health Ontario, and the CDPE have published a report analyzing trends in opioid-related deaths and comparing circumstances of death between two groups: a COVID-19 pandemic cohort and a pre-pandemic cohort.
View